Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8

Benzinga Newsdesk www.benzinga.com Neutral 63.2%

Neg 0% Neu 63.2% Pos 0%

Barclays analyst Gena Wang initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Underweight rating and announces Price Target of $8.